Predictive Role of Soluble IL-6R, TNF-R1/2, and Cell Adhesion Molecules Serum Levels in the Preoperative and Adjuvant Therapy in Women with Nonmetastatic Breast Cancer: A Preliminary Study

Bulska-Będkowska, Weronika; Czajka-Francuz, Paulina; Cisoń-Jurek, Sylwia; Owczarek, Aleksander; Francuz, Tomasz; Chudek, Jerzy

doi:10.1089/jir.2022.0092

Cited by 1 publication

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies performed by Schauer et al elucidated that elevated level of the TNF-α in early BC patients receiving NAT was associated with low relative dose intensity of chemotherapy [39] . In another study, increased baseline serum TNF-α (sTNF-R1) level was associated with pathological response to NAT in BC patients [40] . Jabeen et al also reported that serum TNF-α concentration was lower in BC patients who achieve pathological complete response during NAT with or without bevacizumab treatment [41] .…”

Section: Discussionmentioning

confidence: 96%

Predictive Role of Peripheral Blood Lymphocyte And Cytokine Phenotypes in Patients with Operable Breast Cancer And Neoadjuvant Therapy: A Preliminary Study

Wu,

Ou,

Yuan

et al. 2024

Preprint

View full text Add to dashboard Cite

Background PD-L1 is an indicator for immunotherapy however, the detection is based on biopsy and affected by tumor heterogeneity and patients’ intolerance. This study aimed to explore convenient alternatives for PD-L1 tissue detection. Methods With 134 cases recruitment, the peripheral lymphocyte subtypes and cytokines was detected by flow cytometry and PD-L1 expression in tumor microenvironment (TME) was detected by immunohistochemistry and assessed by two qualified pathologists. Results The patients with positive PD-L1 expression had peripheral CD8+/CD28+ T lymphocytes 20% higher than those with negative expression (p = 0.008) with the area under the receiver operating characteristic curve (AUC) being 0.66 (p = 0.002). Among patients with positive PD-L1 expression and negative neoadjuvant therapy (NAT), peripheral CD8+/CD28+ T lymphocytes were 54% higher than those with negative expression (p = 0.003), with the AUC being 0.68 (p = 0.003). In patients receiving NAT, peripheral TNF-α (p = 0.010), increased from 0.45pg/ml to 0.64pg/ml in positive PD-L1 group, and the AUC was 0.79 (p = 0.012). Among breast cancer patients with negative NAT experience, 1% increase of peripheral CD8+/CD28+ T lymphocytes was associated with a 21% higher probability of positive PD-L1 expression (OR = 1.21, 95%CI = 1.06–1.37) and among patients with NAT, the OR of peripheral TNF-α > 0.5pg/ml was increased to 24.5 for positive TME PD-L1 expression (p = 0.008). Conclusion In breast cancer patients receiving NAT, peripheral TNF-α could be used to predict the TME PD-L1 expression, and in breast cancer patients without NAT, peripheral percentage of CD8+/CD28+ T lymphocytes could be used to predict the TME PD-L1 expression. These biomarkers should be further implemented in practice to guide the immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 96%